Trovagene Inc. (TROV) Shares Down 4.4%
Trovagene Inc. (NASDAQ:TROV) traded down 4.4% during mid-day trading on Monday . The company traded as low as $4.81 and last traded at $4.83, with a volume of 138,613 shares trading hands. The stock had previously closed at $5.05.
A number of equities research analysts have recently issued reports on the company. Piper Jaffray Cos. reiterated a “hold” rating and issued a $5.00 target price (down previously from $8.00) on shares of Trovagene in a research note on Thursday, May 12th. Leerink Swann reiterated a “hold” rating on shares of Trovagene in a research note on Thursday, May 12th. Zacks Investment Research upgraded Trovagene from a “sell” rating to a “hold” rating in a research note on Wednesday, July 13th. Argus lowered Trovagene from a “buy” rating to a “hold” rating in a research note on Thursday, April 28th. Finally, Maxim Group reiterated a “buy” rating on shares of Trovagene in a research note on Monday, June 6th. Seven analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $6.96.
The company’s 50-day moving average price is $4.77 and its 200 day moving average price is $4.76. The firm’s market capitalization is $144.53 million.
Trovagene (NASDAQ:TROV) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.07. On average, analysts forecast that Trovagene Inc. will post ($1.30) EPS for the current fiscal year.
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.